Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxm1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS 2 | | "Ask CAS" for self-help around the clock |
| NEWS 3 | OCT 23 | The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded |
| NEWS 4 | OCT 30 | CHEMLIST enhanced with new search and display field |
| NEWS 5 | NOV 03 | JAPIO enhanced with IPC 8 features and functionality |
| NEWS 6 | NOV 10 | CA/CAplus F-Term thesaurus enhanced |
| NEWS 7 | NOV 10 | STN Express with Discover! free maintenance release Version 8.01c now available |
| NEWS 8 | NOV 20 | CA/CAplus to MARPAT accession number crossover limit increased to 50,000 |
| NEWS 9 | DEC 01 | CAS REGISTRY updated with new ambiguity codes |
| NEWS 10 | DEC 11 | CAS REGISTRY chemical nomenclature enhanced |
| NEWS 11 | DEC 14 | WPIDS/WPINDEX/WPIX manual codes updated |
| NEWS 12 | DEC 14 | GBFULL and FRFULL enhanced with IPC 8 features and functionality |
| NEWS 13 | DEC 18 | CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role |
| NEWS 14 | DEC 18 | CA/CAplus patent kind codes updated |
| NEWS 15 | DEC 18 | MARPAT to CA/CAplus accession number crossover limit increased to 50,000 |
| NEWS 16 | DEC 18 | MEDLINE updated in preparation for 2007 reload |
| NEWS 17 | DEC 27 | CA/CAplus enhanced with more pre-1907 records |
| NEWS 18 | JAN 08 | CHEMLIST enhanced with New Zealand Inventory of Chemicals |
| NEWS 19 | JAN 16 | CA/CAplus Company Name Thesaurus enhanced and reloaded |
| NEWS 20 | JAN 16 | IPC version 2007.01 thesaurus available on STN |
| NEWS 21 | JAN 16 | WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data |
| NEWS 22 | JAN 22 | CA/CAplus updated with revised CAS roles |
| NEWS 23 | JAN 22 | CA/CAplus enhanced with patent applications from India |
| NEWS 24 | JAN 29 | PHAR reloaded with new search and display fields |
| NEWS 25 | JAN 29 | CAS Registry Number crossover limit increased to 300,000 in multiple databases |
| NEWS 26 | FEB 13 | CASREACT coverage to be extended |
| NEWS 27 | Feb 15 | PATDPASPC enhanced with Drug Approval numbers |
| NEWS 28 | Feb 15 | RUSSIAPAT enhanced with pre-1994 records |
| NEWS 29 | Feb 23 | KOREAPAT enhanced with IPC 8 features and functionality |

| | |
|---|---|
| NEWS EXPRESS | NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006. |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS IPC8 | For general information regarding STN implementation of IPC 8 |
| NEWS X25 | X.25 communication option no longer available |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 22:40:46 ON 23 FEB 2007

=> FIL REGISTRY

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 22:41:01 ON 23 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 FEB 2007 HIGHEST RN 922800-14-4
DICTIONARY FILE UPDATES: 22 FEB 2007 HIGHEST RN 922800-14-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10505386.str





chain nodes :
17
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
8-17 9-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-17 9-10 10-11 10-15 11-12
12-13 13-14 14-15
isolated ring systems :
containing 10 :

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR




G1 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sam
SAMPLE SEARCH INITIATED 22:41:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       113 TO ITERATE

100.0% PROCESSED       113 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:          1623 TO     2897
PROJECTED ANSWERS:                0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 22:41:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      2148 TO ITERATE

100.0% PROCESSED      2148 ITERATIONS                                 31 ANSWERS
SEARCH TIME: 00.00.01

L3            31 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     172.10     172.31

FILE 'CAPLUS' ENTERED AT 22:41:34 ON 23 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 23 Feb 2007 VOL 146 ISS 10
FILE LAST UPDATED: 22 Feb 2007 (20070222/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 3 L3

=> d l4 ibib hitstr abs 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:386432 CAPLUS
DOCUMENT NUMBER: 144:425692
TITLE: Methods using TGF-β type I receptor inhibitors and Alk4 inhibitors for treating vascular injuries
INVENTOR(S): Ling, Leona E.; Fu, Kai; Gill, Alan; Gotwals, Philip J.
PATENT ASSIGNEE(S): Biogen Idec Ma Inc., USA
SOURCE: PCT Int. Appl., 228 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2006044509 | A2 | 20060427 | WO 2005-US36770 | 20051013 |
| WO 2006044509 | A3 | 20060817 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-619116P P 20041015
OTHER SOURCE(S): MARPAT 144:425692
IT 672932-52-4 672932-53-5 672932-56-8
RL: DEV (Device component use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TGF-β type I receptor inhibitors and Alk4 inhibitors for treating vascular injuries)
RN 672932-52-4 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(6-chloro-2-pyridinyl)pyrazolo[1,5-c]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 672932-53-5 CAPLUS
CN Pyrazolo[1,5-c]pyrimidine, 2-(6-methyl-2-pyridinyl)-3-[2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 672932-56-8 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-c]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



AB The invention discloses the use of TGF-β type I receptor inhibitors and Alk4 inhibitors and implantable devices including these compds. in treating, preventing, or reducing intimal thickening, vascular remodeling, restenosis (e.g., coronary, peripheral, carotid restenosis), vascular diseases, (e.g., organ transplant-related, cardiac, lung and renal), and hypertension (e.g., primary and secondary hypertension, systolic hypertension, pulmonary hypertension, and hypertension-induced vascular remodeling resulting in target organ damage).

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:220201 CAPLUS
DOCUMENT NUMBER: 140:270867
TITLE: Preparation of pyrazolopyridines as antagonists of Alk 5 and/or Alk 4
INVENTOR(S): Lee, Wen-cherng; Carter, Mary Beth; Sun, Lihong; Lyne, Paul; Chuaqui, Claudio; Zheng, Zhongli; Singh, Juswinder; Boriack-Sjodin, Paula
PATENT ASSIGNEE(S): Biogen, Inc., USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2004022054 | A1 | 20040318 | WO 2003-US27722 | | 20030905 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| CA 2497970 | A1 | 20040318 | CA 2003-2497970 | | 20030905 |
| AU 2003268447 | A1 | 20040329 | AU 2003-268447 | | 20030905 |
| EP 1551398 | A1 | 20050713 | EP 2003-749412 | | 20030905 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | | |
| BR 2003014053 | A | 20050719 | BR 2003-14053 | | 20030905 |
| CN 1694698 | A | 20051109 | CN 2003-824867 | | 20030905 |
| JP 2006502165 | T | 20060119 | JP 2004-534571 | | 20030905 |
| NO 2005001503 | A | 20050321 | NO 2005-1503 | | 20050321 |
| US 2006106033 | A1 | 20060518 | US 2005-526839 | | 20051101 |
| PRIORITY APPLN. INFO.: | | | US 2002-408811P | P | 20020906 |
| | | | WO 2003-US27722 | W | 20030905 |

OTHER SOURCE(S): MARPAT 140:270867

IT 672932-52-4P, [4-[2-(6-Chloropyridin-2-yl)pyrazolo[1,5-c]pyrimidin-3-yl]pyrimidin-2-yl]amine 672932-53-5P, 2-(6-Methylpyridin-2-yl)-3-(2-morpholin-4-ylpyrimidin-4-yl)pyrazolo[1,5-c]pyrimidine 672932-56-8P, [4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-c]pyrimidin-3-yl]pyrimidin-2-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyridines as antagonists of Alk 5 and/or Alk 4 for treating fibrotic disorders or diseases or disorders mediated by an overexpression of TGFβ)

RN 672932-52-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-chloro-2-pyridinyl)pyrazolo[1,5-c]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 672932-53-5 CAPLUS

CN Pyrazolo[1,5-c]pyrimidine, 2-(6-methyl-2-pyridinyl)-3-[2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 672932-56-8 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-c]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



GI



I

AB The title compds. [I; wherein each of X1-X4 is independently CRx or N; provided that only two of X1-X4 can be N simultaneously; each of Y1 and Y2 is independently CRy or N; provided that at least one of Y1 and Y2 must be N; R1 = alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, cyano, guanidino, amidino, carboxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, alkylsulfonylamino, alkoxycarbonyl, alkylcarbonyloxy, urea, thiourea, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfanyl, heterocycloalkyl, heterocycloalkyloxy, etc.; R2 = alkyl, alkenyl, alkynyl, acyl, halo, hydroxy, NH2, NH(alkyl), N(alkyl)2, NH(cycloalkyl), N(alkyl)(cycloalkyl), NH(heterocycloalkyl), NH(heteroaryl), NH-alkylheterocycloalkyl, NH-alkylheteroaryl, NH(aralkyl), cycloalkyl, (cycloalkyl)alkyl, aryl, aralkyl, aroyl, heterocycloalkyl, (heterocycloalkyl)alkyl, etc.; m = an integer of 0-4; n = an integer of 0-3; provided that when m >2, two adjacent R1 or R2 groups can join together to form a 4- to 8-membered optionally substituted cyclic moiety; Rx, Ry = H, alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, cyano, guanidino, amidino, carboxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, cycloalkylcarbonyl, (cycloalkyl)alkylcarbonyl, aroyl, aralkylcarbonyl, etc.] or pharmaceutically acceptable salts or N-oxides thereof. These compds. possess unexpectedly high affinity for transforming growth factor β (TGFβ) type I receptor (Alk 5) and/or activin receptor type I (Alk 4), and can be useful as antagonists thereof for preventing and/or

treating numerous diseases, including fibrotic disorders or diseases or disorders mediated by an overexpression of TGFβ. The fibrotic condition is selected from the group consisting of scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scarring, spinal cord injury, CNS scarring, acute lung injury, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury, glomerulonephritis, diabetic nephropathy, hypertension-induced nephropathy, hepatic or biliary fibrosis, liver cirrhosis, primary biliary cirrhosis, fatty liver disease, primary sclerosing cholangitis, restenosis, cardiac fibrosis, opthalmic scarring, fibrosclerosis, fibrotic cancers, fibroids, fibroma, fibroadenomas, fibrosarcomas, transplant arteriopathy, and keloid. The diseases or disorders mediated by an overexpression of TGFβ are selected from the group consisting of demyelination of neurons in multiple sclerosis, Alzheimer's disease, cerebral angiopathy, squamous cell carcinomas, multiple myeloma, melanoma, glioma, glioblastomas, leukemia, and carcinomas of the lung, breast, ovary, cervix, liver, biliary tract, gastrointestinal tract, pancreas, prostate, and head and neck.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:737760 CAPLUS
DOCUMENT NUMBER: 139:261327
TITLE: Preparation of pyrazolopyrimidines and pyrazolotriazines for treatment of herpes viral infections
INVENTOR(S): Gudmundsson, Kristjan; Johns, Brian A.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2003076441 | A1 | 20030918 | WO 2003-US5704 | | 20030224 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| AU 2003217712 | A1 | 20030922 | AU 2003-217712 | | 20030224 |
| EP 1485385 | A1 | 20041215 | EP 2003-713672 | | 20030224 |
| EP 1485385 | B1 | 20050817 | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | | |
| US 2005124616 | A1 | 20050609 | US 2003-505386 | | 20030224 |
| JP 2005525382 | T | 20050825 | JP 2003-574658 | | 20030224 |
| AT 302203 | T | 20050915 | AT 2003-713672 | | 20030224 |
| ES 2245772 | T3 | 20060116 | ES 2003-3713672 | | 20030224 |
| PRIORITY APPLN. INFO.: | | | US 2002-362298P | P | 20020307 |
| | | | WO 2003-US5704 | W | 20030224 |

OTHER SOURCE(S): MARPAT 139:261327
IT 601521-20-4P 601521-21-5P 601521-37-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazolopyrimidines and pyrazolotriazines for treatment of herpes viral infections)

RN 601521-20-4 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)pyrazolo[1,5-c]pyrimidin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 601521-21-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-7-(methylthio)pyrazolo[1,5-c]pyrimidin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 601521-37-3 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(methylthio)pyrazolo[1,5-c]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




IT 601521-18-0P 601521-19-1P 601521-22-6P
601521-23-7P 601521-24-8P 601521-25-9P
601521-29-3P 601521-30-6P 601521-31-7P
601521-32-8P 601521-33-9P 601521-34-0P
601521-35-1P 601521-36-2P 601521-38-4P
601521-39-5P 601521-40-8P 601521-41-9P
601521-42-0P 601521-43-1P 601521-44-2P
601521-45-3P 601521-46-4P 601521-47-5P
601521-48-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of pyrazolopyrimidines and pyrazolotriazines for treatment of herpes viral infections)

RN 601521-18-0 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 601521-19-1 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 601521-22-6 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, 2-(3-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 601521-23-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-c]pyrimidin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 601521-24-8 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, 2-(3-chlorophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 601521-25-9 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7(6H)-one, 2-(3-chlorophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 601521-29-3 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-N-cyclopentyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 601521-30-6 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 601521-31-7 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, 3-[2-(2-benzothiazolylamino)-4-pyrimidinyl]-N-cyclopentyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 601521-32-8 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[(4-methyl-2-thiazolyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 601521-33-9 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, 3-[2-(1H-benzimidazol-2-ylamino)-4-pyrimidinyl]-N-cyclopentyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 601521-34-0 CAPLUS

CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[[(4-fluorophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 601521-35-1 CAPLUS

CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[(2-phenylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 601521-36-2 CAPLUS

CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-3-[2-[(1,1-dimethylethyl)amino]-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 601521-38-4 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 601521-39-5 CAPLUS
CN Phenol, 4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-c]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)




RN 601521-40-8 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 601521-41-9 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 601521-42-0 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, 2-(4-butoxyphenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 601521-43-1 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(2-methylpropoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 601521-44-2 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(2-methoxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 601521-45-3 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-propoxyphenyl)- (9CI) (CA INDEX NAME)




RN 601521-46-4 CAPLUS
CN Pyrazolo[1,5-c]pyrimidin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(1,1-dimethylethyl)-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 601521-47-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-c]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 601521-48-6 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(1-piperidinyl)pyrazolo[1,5-c]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




GI



I



II

AB Title compds. I [A = (un)substituted heterocyclic; Y, Y1 = n, CH; R1, R5 = H, halogen, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, acyl, CO2H, CONH2, CSNH2, C(:NH)NH2, OH, NH2, SH, S(O)H, SO2H, CN, NO2, N3; R2 = halogen, (un)substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heterocyclic, OH, NH2, SO2NH2; R3, R4 = H, halogen, (un)substituted alkyl, alkenyl, cycloalkyl, aryl, heterocyclic, CO2H, OH, NH2, SO2NH2, acyl; p = 0-2] were prepared for use in the prophylaxis or treatment of a condition or disease associated with a herpes viral infection. Thus, the pyrazolopyrimidine II was prepared from 4-methyl-2-pyrimidinethiol in 8 steps and has IC50 for inhibition of HSV-1 of 0.72 μM.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 16.28 | 188.59 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE | -2.34 | -2.34 |

STN INTERNATIONAL LOGOFF AT 22:41:54 ON 23 FEB 2007